Di mana Profesor Khan menerima pendidikan kedokterannya?

Profesor Khan lulus dari Sekolah Kedokteran Rumah Sakit Guy 1994.

Apa kualifikasi Profesor Khan dalam Gastroenterologi dan Hepatologi?

Beliau adalah Anggota Royal College of Physicians dan telah menyelesaikan pelatihan spesialis di bidang Gastroenterologi dan Hepatologi.

Apa saja peran kunci yang dipegang Profesor Khan dalam karirnya?

Dia telah menjabat sebagai direktur kursus, Direktur Penerimaan dan Inklusivitas, Wakil Tutor Penerimaan, Direktur Studi Klinis, dan Dokter Konsultan di berbagai rumah sakit dan lembaga.

Apa saja kondisi yang diproduksi oleh Profesor Khan dalam merawat?

Profesor Khan berspesialisasi dalam mengobati kondisi seperti tes fungsi hati, nyeri perut, hepatitis virus, hati berlemak, kanker hati, dan memberikan prosedur seperti fibroscan dan endoskopi.

Apa pengalaman Profesor Khan dalam pengajaran dan pendidikan?

Profesor Khan adalah Pendidik Royal College of Physicians bersertifikat, telah mengajar mahasiswa sarjana dan pascasarjana, dan telah menerima beberapa Penghargaan Pengajaran.

Di mana Profesor Khan saat ini berlatih sebagai dokter konsultan?

Profesor Khan adalah Dokter Konsultan di BMI The Clementine Churchill Hospital, St Mary's Hospital - Lindo Wing, The London Clinic, St Mary's and Hammersmith Hospitals, dan Imperial College London Healthcare NHS Trust.

Apa afiliasi akademis Profesor Khan?

Profesor Khan adalah profesor praktik (hepatologi) di Imperial College London.

Apakah Profesor Khan menerima penghargaan atau pengakuan atas karyanya?

Profesor Khan telah menerima beberapa Penghargaan Pengajaran di Imperial College London atas kontribusinya terhadap pendidikan kedokteran.

Apakah Profesor Khan berbicara bahasa apa pun selain bahasa Inggris?

Profesor Khan fasih berbahasa Urdu dan Hindi.

Profesor Shahid Khan

Ahli gastroenterologi

Konsultasikan di:

Rumah Sakit Clementine Churchill - bagian dari Circle Health Group

Operasi

N/A

Pengalaman

30+ bertahun-tahun

Tentang

ist accreditation in General Internal Medicine. He qualified from Guy's Hospital Medical School in 1994 and underwent house-officer posts at Greenwich District Hospital and Guy's Hospital. Professor Khan trained as a senior house officer at Hammersmith, Charing Cross, St Thomas', and West Middlesex Hospitals. He then went on to become a Specialist Registrar in Gastroenterology.

Between 1999 and 2002 he was a Clinical Research Fellow at Imperial College London. He was awarded a PhD from the University of London in 2003 for his studies in liver cancer. Professor Khan completed his senior gastroenterology and specialist Hepatology training at St Mary's Hospital and University College Hospital in London. Professor Khan became a Fellow of the Royal College of Physicians in 2010.

He has since been running a general hepatology and gastroenterology service and founded a dedicated clinic for decompensated cirrhotic patients and also for primary liver cancer. He is also the academic and clinical lead for liver cancer and is a designated endoscopy trainer.

Professor Khan is a certified Royal College of Physicians Educator and teaches both undergraduates and postgraduates. He was the Course Director of the Gastroenterology & Hepatology BSc programme at Imperial College London for several years and is currently the Director of Admissions and Inclusivity for Imperial College School of Medicine. He has received several Teaching Awards at Imperial College London. He also speaks Urdu and Hindi fluently.

]

Pendidikan

Professor of Practice (Hepatology), Imperial College London
Course Director of the Gastroenterology and Hepatology BSc programme, Imperial College London
Director of Clinical Studies, St Mary’s Hospital Campus (2013 – 2016)
Deputy Admissions Tutor, Imperial Medical School (2012 - present)

Pengalaman

More than 30 years of experience
Consultant Physician, BMI The Clementine Churchill Hospital (present)
Consultant Physician, St Mary's Hospital - Lindo Wing (present)
Consultant Physician, The London Clinic (present)
Consultant Physician, St Mary’s and Hammersmith Hospitals
Consultant Physician, Imperial College London Healthcare NHS Trust

penghargaan

Banales J, Marin J, Lamarca A, Rodrigues P, Khan SA, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Rev Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1038/s41575-020-0310-z.
Pericleous M and Khan SA. Epidemiology of HPB Malignancy in the Elderly. EJSO 2020; (in press)
Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD and Khan SA. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020. 72(1):95-103. doi: 10.1016/j.jhep.2019.09.007.
Dumenci OE, Abellona MR U, Khan SA, Holmes E, Taylor-Robinson SD. Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. J Hepat Carcinoma 2020; 7: 1-9.
Yousaf A, Kim J, Eliahoo J, Taylor-Robinson SD and Khan SA. Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis. J Clin Exp Hepatology 2019; J Clin Exp Hepatol. 2019 Nov-Dec;9(6):740-748. doi: 10.1016/j.jceh.2019.08.001. Epub 2019 Aug 19.PMID: 31889756
Khan SA, Genus T, Morement H, Murphy A, Rous B, Tataru B. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma – Letter to the Editor. J Hepatology 2019; 71:1261-1262
Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and Risk Factors. Liver Int 2019. DOI 10.1111/liv.14095
Wadsworth CA, Dixon PH, Taylor-Robinson SD, Kim JU, Zabron AA, Wong JH, Chapman MH, McKay SC, Spalding DR, Wasan HS, Pereira SP, Thomas HC, Whittaker JC, Williamson C and Khan SA. Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a risk factor for Cholangiocarcinoma. J Clin Exp Hep 2019;9(2):171-175. doi: 10.1016/j.jceh.2018.06.521.
Mukherjee SK, Toledano MB, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PloS One 2019;14(4):e0212779. doi: 10.1371
Howell J, Atkinson SR, 1, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019; 116: 56-66.
Appleby RN, Moghul I, Khan SA, Yee M, Manousou P, Dew T, Walters JRF. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: a prospective observational study. PloS One 2019; 25;14(1):e0211348. doi: 10.1371/journal.pone.0211348
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nature Rev Clin Oncol 2018 15(2):95-111. doi: 10.1038/nrclinonc.2017.157..
Shabeer LL and Khan SA. Medical Students' Perception of Undergraduate Hepatology Teaching In The UK - A National Survey. Annual General Meeting of the British-Society-of-Gastroenterology. Gut 2018. BMJ Publishing Group. 67: A278-A278 (Conference Abstract).
Khan SA, McClements S, Reccia I, Evans J, Pai M and Sharma R. The Next Generation of Hepatocellular Cancer Experts – What do they think? Hepatic Onc 2017: 3(4), 213–215.
Carruthers J, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP: Nationwide trends in non-alcoholic steatohepatitis in patients with and without diabetes between 2004 and 2014 in England. Diab Res Clin Prac 2017; 132:102-107.
Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan SA, Fowell A, McPherson S, Newsome PN, Oben J, Jeremy Tomlinson J, Tsochatzis E. Frontline Gastroenterology 2017;8:252–259.
Liu NJ, Chapman R, Lin Y, Bentham A, Tyreman M, Philips N, Khan SA, Molly M. Stevens. Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. Nanoscale 2016; 8(23):11834-9.
Howell J, Khan SA, Knapp S, Thursz MR, Sharma R. The clinical role of circulating free tumour DNA in gastrointestinal malignancy. Transl Res. 2016; pii: S1931-5244(16)30461-3.
Howell J, Khan SA. The Role of miRNAs in Cholangiocarcinoma. Hepat Oncol 2016: 3(2):167-180.
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T. ESMO Clinical Practice Guidelines On behalf of the ESMO Guidelines Working Group: Buliary Tract Cancer. Ann Oncol. 2016;27(s5):v28-v37.
International Webinar on the Management of Hepatocellular Carcinoma for Bayer in the COVID Era (2020)
British Society of Gastroenterology Committee for update of the UK guidelines on the Management of Cholangiocarcinoma (2020)
Plenary Lecture at BASL: What’s New in Cholangiocarcinoma (2019) ...

Rumah Sakit

FAQs

Profesor Khan adalah ahli gastroenterologi dan ahli hepatologi yang berspesialisasi dalam penyakit hati, termasuk kanker hati dan sirosis.

Profesor Shahid Khan

Tentang

Pendidikan

Pengalaman

penghargaan

Rumah Sakit

FAQs

Apa bidang keahlian Profesor Shahid Khan?

Di mana Profesor Khan menerima pendidikan kedokterannya?

Apa kualifikasi Profesor Khan dalam Gastroenterologi dan Hepatologi?

Apa saja peran kunci yang dipegang Profesor Khan dalam karirnya?

Apa saja kondisi yang diproduksi oleh Profesor Khan dalam merawat?

Apa pengalaman Profesor Khan dalam pengajaran dan pendidikan?

Di mana Profesor Khan saat ini berlatih sebagai dokter konsultan?

Apa afiliasi akademis Profesor Khan?

Apakah Profesor Khan menerima penghargaan atau pengakuan atas karyanya?

Apakah Profesor Khan berbicara bahasa apa pun selain bahasa Inggris?

Tentang

Pendidikan

Pengalaman

penghargaan

Rumah Sakit